Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Total Non-Current Liabilities (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Total Non-Current Liabilities for 15 consecutive years, with $123.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 3.03% to $123.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $123.1 million, a 3.03% increase, with the full-year FY2024 number at $143.7 million, up 16.45% from a year prior.
  • Total Non-Current Liabilities was $123.1 million for Q3 2025 at Usana Health Sciences, down from $180.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $196.3 million in Q1 2025 to a low of $108.5 million in Q2 2024.
  • A 5-year average of $146.8 million and a median of $145.8 million in 2022 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: fell 16.57% in 2023, then skyrocketed 66.71% in 2025.
  • Usana Health Sciences' Total Non-Current Liabilities stood at $165.8 million in 2021, then decreased by 10.8% to $147.9 million in 2022, then dropped by 16.57% to $123.4 million in 2023, then rose by 16.45% to $143.7 million in 2024, then dropped by 14.31% to $123.1 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Total Non-Current Liabilities are $123.1 million (Q3 2025), $180.8 million (Q2 2025), and $196.3 million (Q1 2025).